Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
The roles and experiences of adolescents with cystic fibrosis and their parents during transition: A qualitative interview study.
Wyngaert KV, Debulpaep S, Van Biesen W, Van Daele S, Braun S, Chambaere K, Beernaert K. Wyngaert KV, et al. Among authors: van daele s. J Cyst Fibros. 2023 Oct 13:S1569-1993(23)00925-6. doi: 10.1016/j.jcf.2023.10.005. Online ahead of print. J Cyst Fibros. 2023. PMID: 37839982
Additionally, healthcare providers should recognize that imposing restrictive roles may result in parental resistance, but can also foster AYAs' skill development. Future research should examine the short- and long-term impact of role-management interventions in AYAs and t …
Additionally, healthcare providers should recognize that imposing restrictive roles may result in parental resistance, but can also foster A …
Long-term use of tube feeding in children with cystic fibrosis: results from two Belgian CF centers.
Declercq D, Huysentruyt K, Hauser B, De Wachter E, Van Daele S, De Baets F, Van Biervliet S. Declercq D, et al. Among authors: van daele s. Eur J Clin Nutr. 2021 Apr;75(4):620-627. doi: 10.1038/s41430-020-00782-5. Epub 2020 Oct 19. Eur J Clin Nutr. 2021. PMID: 33077878
BACKGROUND: Enteral tube feeding (ETF) is often used in an attempt to optimize the nutritional status. The aim of this study was to observe the long term effect of ETF and to compare the start of ETF with the current European guidelines on nutrition care in CF. ...
BACKGROUND: Enteral tube feeding (ETF) is often used in an attempt to optimize the nutritional status. The aim of this study was to observe …
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. Vissing J, et al. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. J Neurol. 2020. PMID: 32189108 Free PMC article. Clinical Trial.
At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved 'minimal symptom expression' (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531). The long-term …
At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved 'minimal sy …
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. ...Patients who had received placebo during RE …
We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS: E …
The effect of enteral tube feeding in cystic fibrosis: A registry based study.
Libeert D, Declercq D, Wanyama S, Thomas M, Van Daele S, De Baets F, Van Biervliet S. Libeert D, et al. Among authors: van daele s. J Cyst Fibros. 2018 Mar;17(2):264-270. doi: 10.1016/j.jcf.2018.01.004. Epub 2018 Feb 1. J Cyst Fibros. 2018. PMID: 29396026 Free article.
BACKGROUND: Long-term effect of enteral tube feeding (ETF) in cystic fibrosis (CF) remains equivocal. ...
BACKGROUND: Long-term effect of enteral tube feeding (ETF) in cystic fibrosis (CF) remains equivocal. ...
A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, et al. Filleul B, et al. Among authors: van daele s. Leukemia. 1994 Jul;8(7):1153-6. Leukemia. 1994. PMID: 7913513
From this small series, we conclude that a single course of 2-CdA does not eradicate HCL and that persistence of residual leukemic cells appears to be common in patients in complete morphologic remission. Whether persistence of MRD will have an impact on long-term outcome, …
From this small series, we conclude that a single course of 2-CdA does not eradicate HCL and that persistence of residual leukemic cells app …
Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martiat P. Nizet Y, et al. Among authors: van daele s. Blood. 1993 Sep 1;82(5):1618-25. Blood. 1993. PMID: 8364210 Free article.
Within the first 3 months of complete remission, MRD was detectable in 22 of 23 investigated patients and remained so in 19 of 21 patients examined at 6 months, regardless of the long-term clinical outcome. In patients remaining in complete remission at 30 months or more, …
Within the first 3 months of complete remission, MRD was detectable in 22 of 23 investigated patients and remained so in 19 of 21 patients e …